Patients with low miR-374a expression together with high PTEN expression had the longest survival times among advanced-stage patients (Fig. 6k) (P < 0.001) as well was the entire NSCLC cohort (Supplementary Figure 6H) (P = 0.005). This evidence concerns the gene PTEN and non-small cell lung carcinoma.